Alnylam Pharmaceuticals Inc (ALNY.OQ)
ALNY.OQ on NASDAQ Stock Exchange Global Select Market
102.81USD
18 May 2018
102.81USD
18 May 2018
Change (% chg)
$1.17 (+1.15%)
$1.17 (+1.15%)
Prev Close
$101.64
$101.64
Open
$101.31
$101.31
Day's High
$103.14
$103.14
Day's Low
$100.92
$100.92
Volume
243,748
243,748
Avg. Vol
356,982
356,982
52-wk High
$153.80
$153.80
52-wk Low
$63.01
$63.01
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Mar '18 | 21.90 | -1.420 |
| FY 2017 | Dec '17 | 37.92 | -1.479 |
| Sep '17 | 17.10 | -1.339 | |
| Jun '17 | 15.93 | -1.344 | |
| Mar '17 | 18.96 | -1.247 | |
| FY 2016 | Dec '16 | 17.45 | -1.316 |
| Sep '16 | 13.65 | -1.214 | |
| Jun '16 | 8.71 | -1.054 | |
| Mar '16 | 7.34 | -1.208 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 11 | 17.97 | 42.70 | 2.30 | 45.93 |
| Quarter Ending Sep-18 | 11 | 27.04 | 53.80 | 8.00 | 63.15 |
| Year Ending Dec-18 | 14 | 102.74 | 167.40 | 53.00 | 146.88 |
| Year Ending Dec-19 | 17 | 296.05 | 598.37 | 177.90 | 340.13 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 13 | -1.76 | -1.33 | -2.20 | -1.49 |
| Quarter Ending Sep-18 | 13 | -1.86 | -1.44 | -2.11 | -1.39 |
| Year Ending Dec-18 | 15 | -7.04 | -5.70 | -8.19 | -5.02 |
| Year Ending Dec-19 | 17 | -6.12 | -4.57 | -7.96 | -3.11 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 84.06 | 32.75 | |
| P/E High - Last 5 Yrs. | -- | 293.32 | 45.73 | |
| P/E Low - Last 5 Yrs. | -- | 91.63 | 24.23 | |
| Beta | 2.97 | 0.90 | 0.88 | |
| Price to Sales (TTM) | 170.48 | 110.95 | 5.71 | |
| Price to Book (MRQ) | 10.02 | 13.58 | 5.37 | |
| Price to Tangible Book (MRQ) | 10.02 | 14.04 | 6.94 | |
| Price to Cash Flow (TTM) | -- | 71.44 | 23.33 | |
| % Owned Institutions | 96.38 | 12.71 | 2.16 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.31 | 1.50 | |
| Dividend Yield - 5 Year Avg | -- | 0.26 | 1.51 | |
| Dividend 5 Year Growth Rate | -- | 1.66 | 5.32 | |
| Payout Ratio(TTM) | -- | 15.72 | 43.29 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 82.94 | 399.27 | 9.21 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 120.51 | 78.86 | 5.69 | |
| Sales - 5 Yr. Growth Rate | -10.64 | 32.18 | 10.32 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -27.58 | 25.14 | 19.38 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -20.86 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 39.01 | 10.77 | |
| Capital Spending - 5 Yr. Growth Rate | 118.68 | 40.31 | 15.47 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.81 | 2.19 |
| Current Ratio (MRQ) | 8.84 | 5.29 | 2.98 |
| LT Debt to Equity (MRQ) | 13.36 | 22.98 | 12.17 |
| Total Debt to Equity (MRQ) | 13.36 | 24.63 | 16.44 |
| Interest Coverage (TTM) | -- | -99.39 | 32.81 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 40.04 | 54.45 | |
| Gross Margin - 5 Yr. Avg. | -- | 51.16 | 52.21 | |
| EBITD Margin (TTM) | -661.41 | -- | -- | |
| EBITD - 5 Yr. Avg | -480.35 | -575.09 | 10.96 | |
| Operating Margin (TTM) | -680.48 | -718.94 | 4.73 | |
| Operating Margin - 5 Yr. Avg. | -533.41 | -596.41 | 6.40 | |
| Pre-Tax Margin (TTM) | -670.81 | -693.40 | 5.57 | |
| Pre-Tax Margin - 5 Yr. Avg. | -518.10 | -599.76 | 6.81 | |
| Net Profit Margin (TTM) | -670.81 | -694.62 | 1.87 | |
| Net Profit Margin - 5 Yr. Avg. | -496.94 | -602.62 | 3.09 | |
| Effective Tax Rate (TTM) | -- | 22.63 | 23.04 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 18.22 | 23.95 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 128,399 | 22,637,599 | 847,026,665 | |
| Net Income/Employee (TTM) | -861,313 | 2,973,819 | 99,639,257 | |
| Receivable Turnover (TTM) | 5.30 | 20.17 | 5.78 | |
| Inventory Turnover (TTM) | -- | 2.37 | 3.35 | |
| Asset Turnover (TTM) | 0.05 | 0.39 | 0.92 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -31.44 | -1.09 | 10.95 | |
| Return on Assets - 5 Yr. Avg. | -31.82 | -0.58 | 12.32 | |
| Return on Investment (TTM) | -33.58 | 1.57 | 14.38 | |
| Return on Investment - 5 Yr. Avg. | -35.07 | 2.21 | 16.11 | |
| Return on Equity (TTM) | -39.86 | 2.43 | 16.07 | |
| Return on Equity - 5 Yr. Avg. | -40.19 | 3.09 | 17.39 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 14.75 | -0.01 | -10.64 |
| EPS (TTM) % | -38.73 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Alnylam Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 66.44 | 60.70 | 99 | 53 |
| 13 Week | 45.87 | 38.77 | 99 | 65 |
| 26 Week | 152.83 | 133.61 | 99 | 76 |
| 52 Week | 238.72 | 187.09 | 99 | 50 |
| YTD | 227.59 | 187.69 | 99 | 58 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Alnylam Reports Preclinical Data Demonstrating Central Nervous System Delivery Of RNAi Therapeutics
- BRIEF-Alnylam Pharmaceuticals Reports Q1 Loss Per Share Of $1.41
- BRIEF-Alnylam Achieves Alignment With FDA On Accelerated Development Path For Lumasiran
- BRIEF-Alnylam Reports New Clinical Results From The Apollo Phase 3 Study Of Patisiran
- BRIEF-Alnylam Receives Positive Opinion For Orphan Drug Designation In EU For ALN-TTRsc02, For Treatment Of Transthyretin-Mediated Amyloidosis
Institutional Holders
| % Shares Owned: | 94.94% |
| # of Holders: | 441 |
| Total Shares Held: | 95,431,397 |
| 3 Mo. Net Change: | 1,140,412 |
| # New Positions: | 56 |
| # Closed Positions: | 36 |
| # Increased Positions: | 210 |
| # Reduced Positions: | 152 |
| # Net Buyers: | 58 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.